SLN staging accuracy is independent of the size of metastasis and, therefore, is a highly sensitive method of detecting early-stage, metastatic disease. This sensitivity was emphasized in our study, ...

Skipping standard axillary lymph node dissection led to very low rates of axillary recurrence in patients with node-positive breast cancer who became node-negative following neoadjuvant chemotherapy, ...

Sentinel lymph node (SLN) resection has been advocated as an option to reduce morbidity for women undergoing surgery for breast cancer. When the sentinel node is negative for breast cancer, SLN ...

Please provide your email address to receive an email when new articles are posted on . Sentinel lymph node biopsy (SLNB) is a low-risk procedure that can reduce the need for complete lymph node ...

Please provide your email address to receive an email when new articles are posted on . SAN ANTONIO — Omission of completion axillary lymph node dissection did not increase recurrence among patients ...

Recently, omission of axillary lymph node dissection among patients with early breast cancer has been found to have no detrimental effect on outcomes in most cases, continuing a trend toward less ...

Thin Primary Cutaneous Malignant Melanoma: A Prognostic Tree for 10-Year Metastasis Is More Accurate Than American Joint Committee on Cancer Staging During 1990 to 2002, 1,599 patients have undergone ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

Effect of bevacizumab on the risk of chemotherapy-associated anemia in cancer patients: A meta-analysis. Background: Arm lymphedema and limb morbidity in patients going through axillary lymph node ...

The intraoperative molecular tests (RD‑100i OSNA system and Metasin test) are used during breast cancer surgery to detect the presence of 1 or 2 biological markers that are associated with metastatic ...

University of Queensland researchers have received a $3.1 million grant for a trial which could revolutionize endometrial cancer treatment. Research Director Professor Andreas Obermair at UQ's ...